Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk of Hepatitis C Virus Reinfection in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients Achieving Sustained Virologic Response by Antiviral Therapy

NCT04768517 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT04768517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04768517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk of Hepatitis C Virus Reinfection in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients Achieving Sustained Virologic Response by Antiviral Therapy
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Unknown status
Start date
February 9, 2021
Completion date
March 1, 2024
Enrollment
300 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection, hepatitis c virus infection, response to therapy of, human immunodeficiency virus (hiv) coinfection